Home About Cytheris Corporate Overview Executive Management Board of Directors Clinical Advisory Board Academic Partners History Science Portfolio Overview Interleukin-7 NKT Ligands Pipeline & Products Development Pipeline IL-7 in Oncology IL-7 in HIV IL-7 in HCV NKT Ligands Intellectual Property Manufacturing Clinical Trials Clinical Trials Overview IL-7 Oncology Trials IL-7 HIV Trials IL-7 HCV Trials Other IL-7 Trials Business Development News Room Press Releases Calendar of Events Investors Careers Contact Us

DOWNLOAD CORPORATE FACT SHEET (PDF)

Corporate Overview

Cytheris SA is a privately held clinical-stage biopharmaceutical company focused on research and development of new therapies for immune modulation. These drugs aim at reconstituting and enhancing the immune system of patients suffering from cancer, chronic viral or bacterial infections such as HIV and HCV, or lympho-depleting treatments such as chemotherapy, radiotherapy, bone marrow transplantation (BMT) and hematopoietic cell transplantation (HCT).

The company's lead compound, recombinant human Interleukin-7 (r-hIL-7), is a critical growth factor for immune T cell recovery and enhancement. Clinical trials conducted on more than 75 patients in Europe, the U.S. and Canada have suggested the potential of rh-IL-7 to expand and protect CD4+ and CD8+ T-cells.  The Company is currently conducting multiple clinical studies of IL-7 in HIV, HCV and cancer.

A second family of products being developed by the company is based on highly potent NKT/dendritic cell ligands in-licensed from New York University, the Aaron Diamond AIDS Research Center andthe City University of New York. The product family strengthens innate and adaptive immunity connections and will provide new immuno-therapeutic adjuvants for cancer and chronic infectious diseases.

The company operates from its headquarters and laboratories in Issy-les-Moulineaux, a suburb of Paris, and its U.S. subsidiary in Rockville, Maryland.